TUMOR MUTATIONAL BURDEN PREDICTS SURVIVAL IN PATIENTS WITH LOW GRADE GLIOMAS EXPRESSING MUTATED IDH1

Mahmoud S Alghamri^{1,2}, Rohit Thalla^{1,2}, Ruthvik Avvari^{1,2}, Ali Dabaja^{1,2}, Ayman Taher^{1,2}, Lili

Zhao³, Maria G Castro^{1,2} and Pedro R Lowenstein^{1,2}

¹Department of Neurosurgery, University of Michigan Medical School, MSRB II, RM 4570C,

1150 West Medical Center Drive, Ann Arbor, MI 48109-5689, USA.

²Department of Cell and Developmental Biology, University of Michigan Medical School,

MSRB II, RM 4570C, 1150 West Medical Center Drive, Ann Arbor, MI 48109-5689, USA.

³Department of Biostatistics, University of Michigan Medical School, Ann Arbor, MI 48109,

USA.

*CORRESPONDENCE: Pedro R Lowenstein MD PhD

Room 4570B, MSRB II, 1150 West Medical Center Drive, Michigan Medicine, Ann Arbor, MI 48109

e-mail: pedrol@umich.edu

Phone: (734)764-0851

Fax: (734)764-7051

ABSTRACT

Gliomas are the most common primary brain tumors. High Grade Gliomas have a median survival of 18 months, while Low Grade Gliomas (LGG) have a median survival of ~7.3 years. Seventy-six percent of patients with LGG express mutated isocitrate dehydrogenase (mIDH1) enzyme (IDH1^{R132H}). Survival of these patients ranges from 1-15 years, and tumor mutational burden ranges from 8 to 447 total somatic mutations per tumor. We tested the hypothesis that the tumor mutational burden would predict survival of patients with tumors bearing mIDH1^{R132H}. We analyzed the effect of tumor mutational burden on patients' survival using clinical and genomic data of 1199 glioma patients from The Cancer Genome Atlas and validated our results using the Chinese Glioma Genome Atlas. High tumor mutational burden negatively correlates with survival of patients with LGG harboring IDH1^{R132H} (p<0.0001). This effect was significant for both Oligodendroglioma and Astrocytoma LGG-mIDH1 patients. In the TCGA data, median survival of the high mutational burden group was 76 months, while in the low mutational burden group it was 136 months; p < 0.0001. There was no differential representation of frequently mutated genes (e.g., TP53, ATRX, CIC, FUBP) in either group. Gene set enrichment analysis revealed an enrichment in Gene Ontologies related to Cell cycle, DNA damage response in high vs low tumor mutational burden. Finally, we identified a 19 gene signature that predicts survival for patients from both databases. In summary, we demonstrate that tumor mutational burden is a powerful, robust, and clinically relevant prognostic factor of median survival in mIDH1 patients.

INTRODUCTION

Low grade gliomas (LGGs) are slow-growing brain tumors that occur in early adult life and can progress to high grade gliomas (1). Molecular characterizations coupled with the histological classification revealed that a mutation in isocitrate dehydrogenase (mIDH), IDH1^{R132H}, is the main genetic lesion in LGG patients (2-5). Somatic mutation in IDH1, and far less common IDH2, results in excessive production of 2 hydroxyglutarate (2HG) (6-8). 2HG is a potent and competitive inhibitor of α -ketoglutarate (α KG) dependent dioxygenases, which responsible for demethylation of DNA and histones (4, 9). The ensuing hypermethylation phenotype triggers epigenetic reprogramming of the glioma cells' transcriptome (3, 10-13).

The consequences of mIDH1 in glioma cells contribute to cancer development and progression not only by disrupting cell metabolism but also by altering the epigenetic landscape. Metabolically, IDH1 is one of the enzymes that encodes an irreversible reaction in the Tricyclic acid (TCA) cycle. Disruption the IDH1 reaction results in defective mitochondrial oxidative phosphorylation, glutamine metabolism, lipogenesis, glucose sensing, and altering of cellular redox status (8, 14-18). IDH1 also inhibits glioma stem cell differentiation (4, 8), upregulates vascular endothelial growth factor (VEGF) to promote tumor microenvironment formation (19, 20), and produces high levels of hypoxia-inducible factor-1 α (HIF-1 α) to promote glioma invasion (18, 21, 22), which ultimately leads to glioma progression. We have acquired a tremendous insight of the molecular mechanisms of genetic alterations associated with malignant transformation of IDH mutations. This includes activation of NOTCH1, RTK-RAS-PI3K, and Myc-RB1 signaling and/or deleted region of the CDKN2A/2B locus, all of which were found to be altered in progressed mIDH1 GBM samples compare to their lower grade counterparts (2, 23-25). Nevertheless, the exact mechanism that impacts mIDH1 patient survival is still under debate.

In this regard, a significant advance in recent years has identified a set of genetic lesions that are characteristic of mIDH1 and correlate with clinical outcome. This was done in hopes for better prediction of tumor behavior and outcome, including identification of secondary mutations, genetic alterations, methylation patterns, and multivariate prognostic models (26-29). Within the group of IDH-mutant gliomas, presence of 1p/19q co-deletion (IDH-mutant–codel glioma) may present an additional prognostic marker separate from IDH-mutant glioma with intact 1p/19q chromosome arms (IDH-mutant–non-codel glioma). Other genetic alteration affect IDH1 glioma survival includes mutation of *PIK3CA* and *PIK3R1*, and deletion of *CDKN2A* in Astrocytoma mIDH1 (30, 31).

Given the high level of inter-tumor heterogeneity inferred from the presence of variety of genetic lesions and the fact that the IDH1 mutant tumors are resistant to radiotherapy than the wtIDH1 (32, 33), it is tempting to speculate that tumor mutational burden may be a strong predictor for mIDH1 patient prognosis. In most solid cancers, the mutational load negatively impacts the patient survival (34) and it is used as indicator of rapid tumor progression.

In the present study, we analyzed the publicly available TCGA and CGGA datasets in order to correlate the tumor mutational burden with overall survival in mIDH1 LGG subtypes. We found that increasing tumor mutational burden negatively impacts survival of LGG but not GBM. Further analysis of LGG patients revealed that the effect of tumor mutational burden on survival is unique for patients with mIDH1 but not wtIDH1. Moreover, based on the prognosis, we constructed a high-risk gene set that predict poor prognosis in patients with IDH mutation. These data suggest that tumor mutational burden is an independent prognostic factor for glioma patients with IDH1 mutation and can be used as a predictor of patient survival.

RESULTS

Tumor mutational burden unexpectedly predicts increased aggressive clinical course only in LGG-mIDH1

We analyzed the clinical data of 1199 patients form TCGA. Among the TCGA patients we used data from 799 patients for whom there are available complete mutational data. All patients' clinical and mutational data are summarized in Table1 and Table2. We asked if the tumor mutational burden impacts glioma patients' survival. We analyzed the tumor mutational burden in high grade glioma (HGG) and low grade glioma (LGG) in TCGA and validated our results utilizing the CGGA database. We classified all patients according to the tumor mutational burden into two groups (high vs low), based on the median number of mutations for all patients in a group. We found that overall mutational load was higher in HGG compare to the LGG, regardless of the IDH1 mutation (supplement 1A, B). We then applied the 'life test' procedure to compare the survival probabilities between patients with high vs low tumor mutational burden. Surprisingly, there was no differences in survival between HGG with high tumor mutational burden burden as compared to HGG with low tumor mutational burden (Fig 1A).

In contrast, high tumor mutational burden significantly decreased the MS of LGG patients (supplement 2A). We stratified the LGG patients in terms of the IDH1 mutation and found no significant differences in MS between patients with tumors expressing wild type IDH1 and high number of mutations (LGG-wtIDH1^{high}) as compared to patients with LGG-wtIDH1^{low} tumors (Fig 1C). Since the majority of LGG patients harbor a mutation in IDH1, that provides a strong survival benefit, we tested if the effect of a high tumor mutational burden on survival can be detected in LGG patients whose tumors harbor the IDH1 mutation. In the LGG-mIDH1 group,

high tumor mutational burden was negatively correlated with patients' prognosis (Fig 1E). In HGG patients with **m**IDH1 tumors, tumor mutational burden was also negatively correlated with survival, even though the number of patients available to be studied was low (n=14) (supplement 2A).

Within the group of LGG patients, oligodendrogliomas (Oligo) have a better overall survival (OS) than astrocytomas (Astro). We therefore determined if the tumor mutational burden had an effect on survival in each LGG subtype. Tumor mutational burden negatively impacted the prognosis of both Oligo and Astro glioma patients (supplement 2C). There was also no correlation with patient age, gender, treatment or histological classification of LGG-mIDH1^{high} vs LGG-mIDH1^{low} on OS (Table 3). We validated these results by analyzing the role of tumor mutational burden through the web-based analytical tool, i.e., the *cBioPortal* database (35, 36). The results obtained confirm our analysis (supplement 3A-C).

We further validated the effect of tumor mutational burden in LGG-mIDH1 using two approaches.

First, we tested if there was a correlation between the survival rate and tumor burden in all three tumor types. We applied a linear regression model to see if we could predict the "days to death" (dependent variable) of glioma patients based on the tumor mutational burden (independent variable). Since an endpoint is required for linear regression, we only considered the deceased patients in this analysis. Linear regression modeling showed a significant dependency of patients "days to death" on tumor mutational burden only in patients with LGG-mIDH1 tumors (Fig 1B, D, F).

We then validated our TCGA results by studying 286 patients from the CGGA database to further corroborate our hypothesis using a separate data set. In agreement with the results from

6

the TCGA, no difference in survival was seen between GBM-wtIDH1^{high} and GBM-wtIDH1^{low} nor LGG-wtIDH1^{high} and LGG-wtIDH1^{low} (Fig 2A, B). In patients with LGG-mIDH1 tumors, however, LGG-mIDH1^{high} have significantly poorer prognosis compared to LGG-mIDH1^{low} (Figure 2C). These data confirm the effects of tumor mutational burden on survival of patient with LGG expressing the IDH1 mutation, in two international unrelated databases.

Association of genetic alterations with overall survival (OS)

To determine if the differences in tumor mutational load could be explained by changes in the frequency of individual mutations, mutational signatures (COSMIC), or copy number variation, each of these was analyzed in detail. We found that nine out of the top ten most commonly mutated genes are present at the same frequency in both groups. These genes are (IDH1, TP53, ATRX, CIC, FUBP1, TTN, PIK3CA, MUC16, Notch1) (Fig 3A, B). None of these mutations impart a significant difference in OS between LGG-mIDH1^{high} and LGG-mIDH1^{low} (Fig 4A). The COSMIC database has categorized 30 reference mutation spectra signatures based on the analysis of 40 distinct types of human cancer (37). The genetic mutation signatures across all

patients within the LGG-**m**IDH1^{high} and LGG-**m**IDH1^{low} groups were identical (Fig 3A, B, bottom plots). The most common signatures in either group were 1, 6, and 15 (Fig 3 A, B, supplement 4).

We then investigated the effect of the most frequent copy number variations (CNVs) on LGG-**m**IDH1^{high} and LGG-**m**IDH1^{low}. In all LGG-**m**IDH1, the most frequent CNVs are found in the following genes: CCND2, FGF6, FGF23, CHD4, ZNF384 (Fig 4B). All of these CNVs have a negative impact on the OS of LGG-**m**IDH1^{low} (Figure 4B, C). However, these CNVs are all present in a small group of patients (5.5% of LGG-**m**IDH1^{low}, and 6.5% of LGG-**w**tIDH1^{high}).

Overall, these data suggest that tumor mutational burden is a unique and independent prognostic factor that negatively impacts LGG-mIDH1 patient survival.

Unique gene ontology (GO) groups are enriched in the LGG-mIDH1^{high}

Since the hyper-mutational phenotype impacts LGG-mIDH1 but not the LGG-wtIDH1, we hypothesized that LGG-mIDH1^{high} is associated with a differential gene expression profile, which could be used to predict patients' outcome. We performed the differential gene analysis based on tumors with either high or low tumor mutational burden. Using an FDR of 0.01 as the lower limit of significance we identified 1585 genes that were upregulated, and 1865 genes that were downregulated in the LGG-mIDH1^{high}. We then performed gene set enrichment analysis (GSEA) to evaluate the functional aspects of the differentially expressed genes. We compared the differences between significant GOs of LGG-wtIDH1^{high vs low} and LGG-mIDH1^{high vs low}. Results suggested that high tumor mutational burden was associated with upregulation of DNA repair, cell cycle-related processes, and chromosomal remodeling in LGG-wtIDH1^{high vs low} (Fig. 5A, C, supplement 5). In LGG-mIDH1^{high vs low}, there was enrichment in GO families belonging to regulation of cell cycle processes and DNA mismatch repair pathways (Fig 5D, supplement 6). Interestingly, there was a positive enrichment of GO families that belong to RNA and pre-RNA processing in LGG-mIDH1^{high vs low} (Fig 5D). This is consistent with recent report highlighting the effect of enrichment in RNA processing associated GOs on LGG patients' survival (38). We further validated the GSEA analysis using LGG-mIDH1^{high vs low} from the Chinese Glioma Genome Atlas (http://www.cgga.org.cn/). Similar to the TCGA analysis, LGG-mIDH1^{high} from CGGA were enriched in GO related to cell cycle, DNA damage response, and RNA processing (supplement 7). These data elucidate the molecular differences in the high tumor mutational

burden within LGG-**m**IDH1 tumors and suggest that GOs belonging to cell cycle regulation and RNA processing may be negatively correlated with mIDH1 patient survival.

Identification of a set of genes that predict survival in LGG-mIDH1 patients

We aimed to construct an expression gene set that could be used to predict survival in LGGmIDH1. To do so, we first eliminated ontologies that were enriched in both the LGG-wtIDH1^{high} vs. low and LGG-mIDH1^{high vs. low}. The resulting 38 gene sets reflect gene sets selectively enriched in LGG-mIDH1^{high}. LGG-mIDH1^{high} enriched ontologies were associated with DNA repair, cell cycle-related processes, and chromosomal remodeling. To determine if these gene sets correlate with survival, we used the 'significance analysis of prognostic signatures' (SAPS) test (39). SAPS is a powerful tool that computes three p-values (P_{pure} , P_{random} , and $P_{enrichment}$) for candidate prognostic gene sets, and integrates the three p-values in the form of the SAPS *q*-value. Out of 38 gene sets, only 12 gene sets had a significant SAPS score (*q*-value <0.01). Since these 12 gene sets contain a total of 1483 genes, we performed the 'least absolute shrinkage and selection operator' (LASSO) (Fig 6A) to identify those genes within each gene set most associated with survival. From within those 1483 genes, LASSO selected 74 genes that are highly associated with the survival of patients with LGG-mIDH1 tumors (Fig 6A). Thus, using TCGA we identify 74 genes within 12 gene sets which predict LGG-mIDH1 survival.

We then validated the twelve gene sets obtained from our TCGA analysis using the CGGA database. LASSO testing of the CGGA database revealed that only six gene sets (37 genes) predicted survival of patients with LGG-mIDH1 tumors (Fig 6B-G).

From these six gene sets, we selected the one that was most significant in both databases. This gene set contains 19 genes and predicts survival of patients with LGG-mIDH1 tumors with high

statistical significance (TCGA: P<0.0001, CGGA: P<0.00061). The majority of these genes belong to DNA repair pathway (Table 4). Therefore, we propose that this 19 genes' signature could be utilized as a prognostic marker for survival of patients with LGG-mIDH1 tumors.

DISCUSSION

Expression of mIDH1 in LGG results in a hypermethylation phenotype and enhanced patients' survival. In this study, we analyzed the tumor mutational burden, CNVs, mRNA expression, and clinical outcomes utilizing "The Cancer Genome Atlas (TCGA)" database. We validated the results using the Chinese Glioma Genome Atlas (CGGA) database. We propose that tumor mutational burden is a predictor of overall survival in patients with LGG-mIDH1 tumors. Further, based on gene expression levels, we constructed a list of "high-risk" genes which we propose could be used as a prognostic marker of overall survival.

Although the total number of mutations in GBM and LGG-wtIDH1 tumors is higher than in LGG-mIDH1 tumor, the correlation of tumor mutational burden with patient outcome was specific to LGG-mIDH1. This suggests that genomic stability is an important contributor to survival in LGG-mIDH1 patients, albeit, the role of IDH1^{R132H} on mutation rate in LGG tumors remains to be determined.

Tumor mutational burden has been associated with better response to immunotherapy in many, but not all, tumor types (40). However, the tumor mutational burden can also give rise to intratumor heterogeneity which increases treatment resistance, including resistance to immune therapy (41). As recurrent tumors contain an increased tumor mutational burden, and are also more resistant to treatment, and more aggressive than primary tumor (2, 23, 24), there exists a general correlation between tumor mutational burden and tumor progression and aggressiveness.

Previous studies have shown that mutation in PIK3CA and deletion of CDKN2A are associated with poor clinical outcome (30, 31) in LGG. We found that CDKN2A is only present in LGG-**wt**IDH1 (less than 1% of LGG-**m**IDH1), and it was associated with poor clinical outcome in both LGG-**wt**IDH1^{high} and LGG-**wt**IDH1^{low}. Mutation in PIK3CA was present in approximately 7% of LGG-**m**IDH1 patient, but it did not drive unfavorable prognosis in LGG-**m**IDH1^{high}. Moreover, the frequency of these genetic lesions was not different in the high mutation vs. low mutation group.

GSEA suggests that LGG-mIDH1^{high} tumors have positive enrichments in cell cycle regulation and DNA repair GO groups as compare to LGG-mIDH1^{low}. This is likely to be a result of genomic instability associated with high tumor mutational burden in LGG-mIDH1. These data are consistent with our recent study which showed that mIDH1 tumor is associated with epigenetic overexpression of genes involved in DNA repair pathway such as ATM (32). At this stage the activation of DNA repair mechanisms in tumors with high mutational burden could be a cause of increased mutation, or its consequence. Future experimental studies will need to address this issue. Another GO which was unique in LGG-mIDH1^{high} vs LGG-mIDH1^{low} but not in the LGG-wtIDH1 was 'RNA and non-coding RNA processing' (42-45). The role of changes in RNA processing, whether causal or effect of high levels of mutation, will also need to be evaluated in forthcoming studies.

In summary, we propose that the tumor mutational burden could be used as a potentially highly reliable marker of overall survival in patients with LGG-mIDH1 tumors. Furthermore, we identified a sequence of 19 genes whose expression levels correlate significantly with the OS in this group of patients. As our data were established using the TCGA database and validated using the CGGA database, we propose that our results have high clinical statistical significance.

We believe our results are of clinical relevance for therapeutic decisions, and the stratification of patients for clinical trials.

METHODS

Source of data and analyses

All clinical, RNAseq, CNVs, and mutational TCGA data were downloaded from the broad institute firebrowse (46) (http://firebrowse.org/?cohort=GBMLGG&download_dialog=true#). CGGA data were downloaded from the CGGA website (http://www.cgga.org.cn/). Patients were categorized according to their mIDH1 status, tumor grade, and tumor mutational load (high vs low). cBioportal platform was used to validate the effect of mutation load on survival of patients with IDH1 mutation. The pan-cancer LGG or GBM cohort were selected and patients were screened for the IDH1 mutation. Classification of mutation load into four groups was done in a web-based analytical tool the cbioportal website. For mutations and CNVs frequency analysis, data from all patients were converted into matrix files and an in-house developed R-script was used to determine the frequency of each mutation in all the analyzed groups.

Mutation analysis

Mutation analysis was done through the Broad's institute firebrowse stringent filtering and annotation pipeline to obtain a uniform set of mutation calls (46-49). In brief, the number of mutations and the number of covered bases for each gene were tabulated. The significant metric was calculated for each gene, using the lawrence et al methods (MutSigCV) which measure the significance of mutation burden (50). MutSigCV determines the P value for observing the given quantity of non-silent mutations in the gene, given the background model determined by silent (and noncoding) mutations in the same gene and the neighbouring genes of covariate space (49).

Survival analysis

Survival data was censored at the last date the patient was known to be alive. Survival functions were estimated by the Kaplan-Meier method and compared using the log-rank test. The median survival time is calculated as the smallest survival time for which the survivor function is less than or equal to 0.5. Cox proportional hazards regression was used to assess the effect of mutation numbers and IDH mutation status on patient survival. In the Cox model, an interaction between the tumor mutational burden and IDH mutation is tested to estimate the effect of mutation numbers with and without the IDH mutation. The assumptions of proportional hazard and linear form of covariates were assessed by martingale residuals plots and the Kolmogorov-type supremum test. All analyses for survival data were done using SAS 9.4 software. P < 0.05 was considered significant.

For regression analysis, only the deceased patients from each group were considered. Linear regression analysis was performed for the "days to death" as dependent variable vs the number of mutated genes per patient (independent variable). Analysis was done using STATA 15.1 software. P < 0.05 was considered significant.

For Significance Analysis of Prognostic Signatures (SAPS), significant gene sets enriched in LGG-**m**IDH1^{high} were used to compute the true gene set that can predict survival. SAPS was ran using the Bioconductor R package "SAPS" <u>https://rdrr.io/bioc/saps/man/saps.html</u>.. All gene sets were compared in their ability to predict the survival based on the three P-values computed by SAPS (P_{pure} , P_{random} , and $P_{enrichment}$) (39). Only gene sets with integrated Q-value <0.01 were considered significant.

GSEA analysis

All patients were screened for the tumor grade, mutations load, and IDH1 status. Rank file was created by implementing R script from Bader lab (<u>https://github.com/BaderLab/EM-tutorials-</u>

<u>docker/blob/master/R_scripts/supplemental_protocol2_rnaseq.R</u>). The gmt file downloaded from broad institute website (<u>http://software.broadinstitute.org/gsea/index.jsp</u>) and it contains all gene ontology (GO) sets to be included In the GSEA analysis. File for positively and negatively enriched groups were used as input files to create the enrichment map in cytoscape.

ACKNOWLEDGEMENTS

We thank the consulting for statistics, computing and analytics research (CSCAR) at the university of Michigan for the helpful input. We thank the support and academic leadership of Dr. Karin Muraszko, and the administrative and technical support of Angela Collada, and Marta Edwards, respectively. The content is solely the responsibility of the authors. This work was supported by 'National Institutes of Health/National Institute of Neurological Disorders & Stroke (NIH/NINDS) Grants [R37-NS094804, R01-NS105556, R21-NS107894 and

Rogel Cancer Center Scholar Award to M.G.C.]; NIH/NINDS Grants [R01-NS076991, R01-

NS082311, and R01-NS096756 to P.R.L.]; NIH/NIBIB [R01-EB022563 and NCI/UO1-CA-224160 to M.G.C. and P.R.L.]; the Department of Neurosurgery; Leah's Happy Hearts

Foundation, ChadThough Foundation, Pediatric Brain Tumor Foundation, and Smiles for Sophie Forever Foundation [to M.G.C. and P.R.L]. RNA Biomedicine Grant [F046166 to M.G.C.] NIH/NCI [T32- CA009676 Post-doctoral Fellowship to M.S.A].

CONFLICT OF INTEREST

Authors declare no conflict of interest.

REFERENCES

1 Michele Ceccarelli, F.B., Tathiane Malta, Thais Sabedot, Sofie Salma, Bradley Murray, Olena Morozova, Antonio Lavarone, Roel Verhaak. (2016) Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Blioma. *Cell reports*, in press., 550-563.

2 Bai, H., Harmanci, A.S., Erson-Omay, E.Z., Li, J., Coskun, S., Simon, M., Krischek, B., Ozduman, K., Omay, S.B., Sorensen, E.A. *et al.* (2016) Integrated genomic characterization of IDH1-mutant glioma malignant progression. *Nature genetics*, **48**, 59-66.

3 Turcan, S., Rohle, D., Goenka, A., Walsh, L.A., Fang, F., Yilmaz, E., Campos, C., Fabius, A.W., Lu, C., Ward, P.S. *et al.* (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature*, **483**, 479-483.

Lu, C., Ward, P.S., Kapoor, G.S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C.R., Khanin, R., Figueroa, M.E., Melnick, A. *et al.* (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. *Nature*, **483**, 474-478.

5 Dominik Sturm, H.W., Volker Hovestadt, Dong-Anh Khuong-Quang, David T.W. Jones, Carolin Konermann, Elke Pfaff, Martje Tonjes, Martin Sill, Sebastian Bender, Marcel Kool. (2012) Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. *Cancer cell*, **22**.

Jin, G., Reitman, Z.J., Duncan, C.G., Spasojevic, I., Gooden, D.M., Rasheed, B.A., Yang, R., Lopez, G.Y., He, Y., McLendon, R.E. *et al.* (2013) Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. *Cancer research*, **73**, 496-501.

7 Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E. *et al.* (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer cell*, **17**, 225-234.

8 Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C. *et al.* (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature*, **462**, 739-744.

9 Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F. *et al.* (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer cell*, **18**, 553-567.

Liu, X.Y., Gerges, N., Korshunov, A., Sabha, N., Khuong-Quang, D.A., Fontebasso, A.M., Fleming, A., Hadjadj, D., Schwartzentruber, J., Majewski, J. *et al.* (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. *Acta neuropathologica*, **124**, 615-625.

Jiao, Y., Killela, P.J., Reitman, Z.J., Rasheed, A.B., Heaphy, C.M., de Wilde, R.F., Rodriguez, F.J., Rosemberg, S., Oba-Shinjo, S.M., Nagahashi Marie, S.K. *et al.* (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. *Oncotarget*, **3**, 709-722.

Lai, A., Kharbanda, S., Pope, W.B., Tran, A., Solis, O.E., Peale, F., Forrest, W.F., Pujara, K., Carrillo, J.A., Pandita, A. *et al.* (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, **29**, 4482-4490.

Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P. *et al.* (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer cell*, **17**, 98-110.

14 Izquierdo-Garcia, J.L., Viswanath, P., Eriksson, P., Chaumeil, M.M., Pieper, R.O., Phillips, J.J. and Ronen, S.M. (2015) Metabolic reprogramming in mutant IDH1 glioma cells. *PloS one*, **10**, e0118781.

15 Karpel-Massler, G., Ishida, C.T., Bianchetti, E., Zhang, Y., Shu, C., Tsujiuchi, T., Banu, M.A., Garcia, F., Roth, K.A., Bruce, J.N. *et al.* (2017) Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. *Nature communications*, **8**, 1067.

16 Ronnebaum, S.M., Ilkayeva, O., Burgess, S.C., Joseph, J.W., Lu, D., Stevens, R.D., Becker, T.C., Sherry, A.D., Newgard, C.B. and Jensen, M.V. (2006) A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. *The Journal* of biological chemistry, **281**, 30593-30602.

17 Seltzer, M.J., Bennett, B.D., Joshi, A.D., Gao, P., Thomas, A.G., Ferraris, D.V., Tsukamoto, T., Rojas, C.J., Slusher, B.S., Rabinowitz, J.D. *et al.* (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. *Cancer research*, **70**, 8981-8987.

18 Reitman, Z.J., Duncan, C.G., Poteet, E., Winters, A., Yan, L.J., Gooden, D.M., Spasojevic, I., Boros, L.G., Yang, S.H. and Yan, H. (2014) Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. *The Journal of biological chemistry*, **289**, 23318-23328.

Saetta, A.A., Levidou, G., El-Habr, E.A., Panayotidis, I., Samaras, V., Thymara, I., Sakellariou, S., Boviatsis, E., Patsouris, E. and Korkolopoulou, P. (2011) Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome. *Virchows Archiv*, **458**, 749-759.

Yalaza, C., Ak, H., Cagli, M.S., Ozgiray, E., Atay, S. and Aydin, H.H. (2017) R132H Mutation in IDH1 Gene is Associated with Increased Tumor HIF1-Alpha and Serum VEGF Levels in Primary Glioblastoma Multiforme. *Ann Clin Lab Sci*, **47**, 362-364.

Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y. *et al.* (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. *Science (New York, N.Y.)*, **324**, 261-265.

22 Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Wang, P., Xiao, M.T. *et al.* (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. *Cancer cell*, **19**, 17-30.

Hiromichi Suzuki, K.A., Kenichi Chiba, Yusuke Sato, Yusuke Shiozawa, Yuichi Shiraishi, Teppei Shimamura, Atsushi Niida, Kazuya Motomura, Fumiharu Ohka, Takashi Yamamoto, Ichiro Ito, Satoru Miyano, Atsushi Natsume, Seishi Ogawa. Mutational landscape and clonal architecture in grade II and III gliomas. *Nature genetics*, **47**, 458-468.

Johnson, B.E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C.Y., Fouse, S.D., Yamamoto, S., Ueda, H., Tatsuno, K. *et al.* (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. *Science (New York, N.Y.)*, **343**, 189-193.

25 Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T.S., Salama, S.R., Murray, B.A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S.M. *et al.* (2016) Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. *Cell*, **164**, 550-563.

Li, Z.-H., Guan, Y.-L., Liu, Q., Wang, Y., Cui, R. and Wang, Y.-J. (2019) Astrocytoma progression scoring system based on the WHO 2016 criteria. *Scientific reports*, **9**, 96.

Hu, X., Martinez-Ledesma, E., Zheng, S., Kim, H., Barthel, F., Jiang, T., Hess, K.R. and Verhaak, R.G.W. (2017) Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. *Neuro-oncology*, **19**, 786-795.

Reis, G.F., Pekmezci, M., Hansen, H.M., Rice, T., Marshall, R.E., Molinaro, A.M., Phillips, J.J., Vogel, H., Wiencke, J.K., Wrensch, M.R. *et al.* (2015) CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas. *Journal of Neuropathology & Experimental Neurology*, **74**, 442-452.

29 Cimino, P.J., Zager, M., McFerrin, L., Wirsching, H.-G., Bolouri, H., Hentschel, B., von Deimling, A., Jones, D., Reifenberger, G., Weller, M. *et al.* (2017) Multidimensional scaling of diffuse gliomas:

application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. *Acta Neuropathologica Communications*, **5**, 39.

Aoki, K., Nakamura, H., Suzuki, H., Matsuo, K., Kataoka, K., Shimamura, T., Motomura, K., Ohka, F., Shiina, S., Yamamoto, T. *et al.* (2017) Prognostic relevance of genetic alterations in diffuse lowergrade gliomas. *Neuro-oncology*, **20**, 66-77.

Draaisma, K., Wijnenga, M.M., Weenink, B., Gao, Y., Smid, M., Robe, P., van den Bent, M.J. and French, P.J. (2015) PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. *Acta Neuropathol Commun*, **3**, 88.

Nunez, F.J., Mendez, F.M., Kadiyala, P., Alghamri, M.S., Savelieff, M.G., Garcia-Fabiani, M.B., Haase, S., Koschmann, C., Calinescu, A.A., Kamran, N. *et al.* (2019) IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. *Science translational medicine*, **11**.

Wahl, D.R., Dresser, J., Wilder-Romans, K., Parsels, J.D., Zhao, S.G., Davis, M., Zhao, L., Kachman, M., Wernisch, S., Burant, C.F. *et al.* (2017) Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. *Cancer research*, **77**, 960-970.

Klebanov, N., Artomov, M., Goggins, W.B., Daly, E., Daly, M.J. and Tsao, H. (2019) Burden of unique and low prevalence somatic mutations correlates with cancer survival. *Scientific reports*, **9**, 4848.

Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E. *et al.* (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*, **6**, pl1.

Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E. *et al.* (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*, **2**, 401-404.

Tate, J.G., Bamford, S., Jubb, H.C., Sondka, Z., Beare, D.M., Bindal, N., Boutselakis, H., Cole, C.G., Creatore, C., Dawson, E. *et al.* (2018) COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic acids research*, **47**, D941-D947.

Chai, R.C., Li, Y.M., Zhang, K.N., Chang, Y.Z., Liu, Y.Q., Zhao, Z., Wang, Z.L., Chang, Y.H., Li, G.Z., Wang, K.Y. *et al.* (2019) RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. *JCl Insight*, **5**.

Beck, A.H., Knoblauch, N.W., Hefti, M.M., Kaplan, J., Schnitt, S.J., Culhane, A.C., Schroeder, M.S., Risch, T., Quackenbush, J. and Haibe-Kains, B. (2013) Significance analysis of prognostic signatures. *PLoS Comput Biol*, **9**, e1002875.

40 Ribas, A. and Wolchok, J.D. (2018) Cancer immunotherapy using checkpoint blockade. *Science* (*New York, N.Y.*), **359**, 1350.

41 Marusyk, A., Almendro, V. and Polyak, K. (2012) Intra-tumour heterogeneity: a looking glass for cancer? *Nature Reviews Cancer*, **12**, 323-334.

42 Wang, Z.H., Guo, X.Q., Zhang, Q.S., Zhang, J.L., Duan, Y.L., Li, G.F. and Zheng, D.L. (2016) Long non-coding RNA CCAT1 promotes glioma cell proliferation via inhibiting microRNA-410. *Biochem Biophys Res Commun*, **480**, 715-720.

43 Wang, R., Li, Y., Zhu, G., Tian, B., Zeng, W., Yang, Y. and Li, Z. (2017) Long noncoding RNA CASC2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt/beta-catenin signaling pathway. *Neuropsychiatr Dis Treat*, **13**, 1805-1813.

44 Hu, L., Lv, Q.L., Chen, S.H., Sun, B., Qu, Q., Cheng, L., Guo, Y., Zhou, H.H. and Fan, L. (2016) Up-Regulation of Long Non-Coding RNA AB073614 Predicts a Poor Prognosis in Patients with Glioma. *Int J Environ Res Public Health*, **13**, 433.

Li, J., Wang, Y.M. and Song, Y.L. (2016) Knockdown of long noncoding RNA AB073614 inhibits glioma cell proliferation and migration via affecting epithelial-mesenchymal transition. *Eur Rev Med Pharmacol Sci*, **20**, 3997-4002.

The Cancer Genome Atlas Research, N., Chang, K., Creighton, C.J., Davis, C., Donehower, L., Drummond, J., Wheeler, D., Ally, A., Balasundaram, M., Birol, I. *et al.* (2013) The Cancer Genome Atlas Pan-Cancer analysis project. *Nature genetics*, **45**, 1113.

47 Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S. and Getz, G. (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature*, **505**, 495-501.

48 (2016) The Cancer Genome Atlas. TCGA Data Portal Overview. in press.

49 Center, B.I.T.G.D.A. (2016) Mutation Analysis (MutSig 2CV v3.1). *Broad Institute of MIT and Harvard*, in press.

Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A. *et al.* (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature*, **499**, 214-218.

FIGURES LEGENDS

Figure 1. Poor prognosis in mIDH1 patients from TCGA with high mutational burden. (A) Kaplan-Meier survival of GBM-wtIDH1 patients with high mutational burden (red) or low mutational burden (black) from TCGA. There was no significant difference in survival between groups (Hazard Ratio (HR)=0.925, CI [0.651-1.313]) (B) Linear regression model of patient's "days to death" vs mutational burden/patient in GBM-wtIDH1. There was no correlation between patients' "days to death" and mutational load. (C) Kaplan-Meier curves of LGGwtIDH1 patients classified according to mutational burden and IDH1 mutation in TCGA. There is no difference in survival between LGG-wtIDH1^{high} and LGG-wtIDH1^{low} (HR=0.686, CI [0.393-1.196]) (**D**) Linear regression model of patient's "days to death" vs mutation burden/patient in LGG-wtIDH1. There was no correlation between patients' "days to death" and mutational load. (E) LGG-mIDH1^{high} have statistically significantly decreased median survival as compared to LGG-mIDH1^{low} (HR=0.486, CI [0.294-0.794]). (F) Linear regression model of patient's "days to death" vs mutation burden/patient in LGG-mIDH1. There is a significant correlation between patients' days to death and mutation load/patient in LGG-mIDH1 only (R=-0.39, P<0.001).

Figure 2. Poor prognosis in mIDH1 patients with high mutational burden in CGGA.

(A) Kaplan-Meier survival of GBM-wtIDH1 patients with high mutational burden (red) or low mutational burden (black) in CGGA (HR=0.91, CI [0.651-1.18]). There is no statistically significant difference between both groups. (B) Kaplan-Meier of LGG-wtIDH1 patients classified according to mutational burden and IDH1 mutation in CGGA. There is no difference in survival between LGG-wtIDH1^{high} LGG-wtIDH1^{low} (HR=0.644, CI [0.329-1.18]). There is no

statistically significant difference between both groups. (C) Kaplan-Meier of LGG-mIDH1 patients classified according to mutational burden and IDH1 mutation in CGGA. There is a statistically significant difference in survival between LGG-mIDH1^{high} vs LGG-mIDH1^{low} (HR=0.236, CI [0.11-0.5]) (p<0.001).

Figure 3. Somatic genetic alterations identified in LGG-mIDH1 according to the tumor mutational burden. The upper plot shows the mutation rate for each tumor sample. Middle plot: Heatmap of most frequent somatic mutations identified in LGG-mIDH1^{high} (**A**) vs LGG**wt**IDH1^{low} (**B**). Mutation types are color-coded according to the legend. Lower plot: mutational signature analysis between LGG-mIDH1^{high} vs LGG-mIDH1^{low}, respectively.

Figure 4. Mutations frequency and Hazard ratios (HRs) for OS in Cox regression model in LGG-mIDH1^{high} vs LGG-mIDH1^{low}. (A) HRs for OS in Cox regression model according to the presence or absence of the frequently mutated genes among the groups. (B) The most frequent CNVs in high vs low mutation in LGG-mIDH1. (C) HRs for OS in Cox regression model according to the presence or absence of the frequently CNVs among the groups.

Figure 5. Gene set enrichment analysis (GSEA) of high vs low mutation load in LGGwtIDH1 and LGG-mIDH1. (A, B) Cytoscape map visualization of the positive (red) and negative (blue) enriched GO groups in high vs low mutation load in LGG-wtIDH1 (A) and LGG-mIDH1 (B). (C, D) Enrichment plots of the top significantly altered GO in the high vs low mutation load in LGG-wtIDH1 and LGG-mIDH1.

Figure 6. Kaplan-Meier survival of the high risk and low risk genes in LGG-mIDH1. (A) Flow chart illustrating the construction of high-risk gene set in LGG-mIDH1. Significant gene sets in LGG-mIDH1 were selected based om GSEA analysis. SAPS analysis was done to test the

significant prognostic gene sets. Finally, LASSO was performed to predict the genes that mostly impact survival. (**B-G**) Kaplan-Meier of the high-risk vs low risk patients based on the 37 candidate genes that predict survival in all 6 gene sets in TCGA (training) and CGGA (validation) dataset. We propose the sequence of 19 genes in **B** as a predictor of survival in LGG-**m**IDH1.

		LGG				GBM	
Descriptors		wtIDH1 High	wtIDH1 Low	mIDH1 High	mIDH1 Low	wtIDH1 High	wtIDH1 Low
Gender, n(%)	Male	30 (51.72)	34 (59.65)	121 (60.5)	100 (50)	79 (56.43)	100 (71.43)
	Female	28 (48.28)	23 (40.35)	79 (39.5)	100 (50)	61 (43.57)	40 (28.57)
Age, median (25 th - 75 th)		58 (49-63)	41 (29-57)	44 (37-55)	34 (29- 41)	58 (50- 67)	65 (58- 73)
Dediction	Yes	45 (77.59)	30 (52.63)	123 (61.5)	98 (49)	106 (75.71)	111 (79.29)
Therapy,	No	8 (13.79)	21 (36.84)	67 (33.5)	90 (45)	22 (15.71)	24 (17.14)
II(70)	NA	5 (8.62)	6 (10.53)	10 (5)	12 (6)	12 (8.57)	5 (3.57)
TMZ, n (%)		21 (36)	25 (43)	52 (26)	42 (21)	41 (29)	44 (31)
Race, n(%)	Asian	1 (1.72)	1 (1.75)	5 (2.5)	1 (0.5)	2 (1.43)	3 (2.14)
Race, n(%)	Black or African American	5 (8.62)	4 (7.02)	7 (3.5)	5 (2.5)	10 (7.14)	7 (5)
	White	52 (89.66)	49 (85.96)	187 (93.5)	187 (93.5)	126 (90)	126 (90)
	Other	0 (0)	3 (5.26)	1 (0.05)	7 (3.5)	2 (1.43)	4 (2.86)
Median Survival (days)		686	1578	2282	4084	427	414
Histology	Astrocytoma	32 (55.17)	26 (45.61)	67 (33.5)	69 (34.5)	NA	NA
(LGG),	Oligoastrocytoma	12 (20.69)	9 (15.79)	50 (25)	59 (29.5)	NA	NA
n(%)	Oligodendroglioma	14 (24.14)	22 (38.6)	83 (41.5)	72 (36)	NA	NA
Histology (GBM), n(%)	Glioblastoma Multiforme (GBM)	NA	NA	NA	NA	8 (5.71)	3 (2.14)
	Treated Primary GBM	NA	NA	NA	NA	1 (0.71)	3 (2.14)
	Untreated Primary (De Novo) GBM	NA	NA	NA	NA	131 (93.57)	134 (95.71)
1P 19Q n(%)		3 (5.17)	13 (22.81)	78 (39.00)	77 (38.5)	0 (0)	0 (0)

Table 1. Clinical Characteristic of TCGA patients

LGG: Low grade glioma, mIDH: mutation in isocitrate dehydrogenase. TMZ: Temazolamide

		LGG				GBM	
Descriptors		wtIDH1	wtIDH1	mIDH1	mIDH1	wtIDH1	wtIDH1
-		High	Low	High	Low	High	Low
Gender, n(%)	Male	17 (47.22)	22 (61.11)	30 (53.57)	44 (78.57)	22 (55.00)	20 (50.00)
	Female	19 (42.88)	14 (38.99)	26 (46.43)	12 (21.43)	18 (45.00)	20 (28.57)
Age at Diagnosis, median (25th and 75th percentile)		40 (34-48)	38 (28-43)	42 (35-45)	36 (31-42)	56 (45-63)	49 (34-60)
RadiationTherapy,n(%)	Yes	27 (75)	27 (75)	37 (66.07)	41 (73.21)	28 (63.64)	31 (77.5)
	No	5 (13.89)	5 (13.89)	8 (14.29)	8 (14.29)	3 (6.82)	4 (10)
	NA	4 (11.11)	4 (11.1)	11 (19.64)	7 (12.5)	9 (20.45)	5 (12.5)
Median Survival (days)		1342	2210	2982	Undefined	310	765
Histological Type, n(%)	Astrocytoma	12 (33.33)	16 (44.44)	17 (30.36)	7 (12.5)	NA	NA
	Oligoastrocytoma	20 (55.56)	17 (47.22)	29 (51.79)	33 (58.93)	NA	NA
	Oligodendroglioma	4 (11.11)	3 (8.33)	10 (17.86)	16 (28.57)	NA	NA
Subtype, n(%)	Glioblastoma Multiforme (GBM)	NA	NA	NA	NA	24 (60)	20 (50)
	Primary GBM	NA	NA	NA	NA	16 (40)	20 (50)
	Primary	23 (63.89)	25 (69.44)	27 (48.21)	51 (91.07)	16 (40)	20 (50)
	Recurrent	13 (36.11)	11 (30.56)	29 (51.79)	5 (8.93)	24 (60)	20 (50)

Table 2. Clinical Characteristic of CGGA patients

LGG: Low grade glioma, mIDH1: mutation in isocitrate dehydrogenase.

	LGG-mIDH1 ^{low}			LGG-mIDH1 ^{high}		
	Mean	Upper	Lower	Mean	Upper	Lower
Gender	1.176	2.399	0.576	0.8065	1.501	0.4335
Age	0.7026	1.91	0.2585	0.8382	1.578	0.4452
Radiotherapy	1.655	3.569	0.7676	1.352	2.615	0.699
Oligodendro	0.5396	1.13	0.2576	1.285	2.391	0.6901
Oligoastro	1.26	2.86	0.5553	0.5971	1.108	0.2452
Astro	1.676	3.774	0.7444	1.387	2.683	0.7167
1P 19Q Co- deletion	0.7042	1.494	0.3320	0.8084	1.517	0.4307
TMZ	0.9604	2.078	0.4438	1.746	3.145	0.8928

Table 3. Univariate Cox analysis in TCGA LGG-mIDH1

LGG: Low grade glioma, Oigodendro: Oligodendroglioma, Astro: Astrocytoma, Oligoastro:

Oligoastrocytoma, mIDH1: mutation in isocitrate dehydrogenase. TMZ: Temazolamide

Gene ID	Gene symbol	Gene Name	Pathway		
994	CDC25B	cell division cycle 25B	DNA damage-induced cell cycle checkpoints		
1019	CDK4	cyclin dependent kinase 4	DNA Damage Response		
7161	TP73	tumor protein p73	DNA Damage Response (only ATM dependent)		
144455	E2F7	E2F transcription factor 7	Gene Expression		
1908	EDN3	endothelin 3	Class A/1 (Rhodopsin-like receptors)		
983	CDK1	cyclin dependent kinase 1	DNA Damage Response		
1647	GADD45A	growth arrest and DNA damage inducible alpha	DNA Damage Response		
51379	CRLF3	cytokine receptor like factor 3	DNA/Protein Binding		
55023	PHIP	pleckstrin homology domain interacting protein	Protein Binding		
55544	RBM38	RNA binding motif protein 38	RNA Binding		
11113	CIT	citron rho-interacting serine/threonine kinase	G13 Signaling Pathway		
85456	TNKS1BP1	tankyrase 1 binding protein 1	Deadenylation of mRNA		
219736	STOX1	storkhead box 1	NA		
58525	WIZ	WIZ zinc finger	NA		
153090	DAB2IP	DAB2 interacting protein	ARMS-mediated activation		
7027	TFDP1	transcription factor Dp-1	Activation of BH3-only proteins		
23019	CNOT1	CCR4-NOT transcription complex subunit 1	RNA degradation		
10397	NDRG1	N-myc downstream regulated 1	Gene Expression		
2810	SFN	stratifin DNA Damage Response			

Table 4. 19-genes signature that predicts survival in LGG-mIDH1

ABBREVIATIONS

IDH1	Isocitrate Dehydrogenase1
MS	Median Survival
LGG-mIDH1 ^{high}	Low Grade glioma patients with IDH1 mutation and high mutational burden
LGG-mIDH1 ^{low}	Low Grade glioma patients with IDH1 mutation and low mutational burden
OS	Overall Survival
2HG	2-Hydroxy glutarate
αKG	α-ketoglutarate
VEGF	Vascular endothelial growth factor
HIF-1a	hypoxia-inducible factor-1α
РІКЗСА	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
CDKN2A	Cyclin Dependent Kinase Inhibitor 2A
LGG	Low Grade Glioma
HGG	High Grade Glioma
GBM	Glioblastoma Multiforme
TCGA	The Cancer Genome Atlas
CGGA	Chinese Glioma Genome Atlas
Oligo	oligodendrogliomas
Astro	astrocytoma

TCGA













A Mutational profiling of LGG-mIDH1high



B Mutational profiling of LGG-mIDH1^{low}



LGG-mIDH1^{low} samples



A LGG-wtIDH1 High vs Low mutation

B LGG-mIDH1 High vs Low mutation



